Clinical evaluation of fleroxacin in the treatment of bone and joint infections.
The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.7%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.
Liu
Y C
YC
Department of Medicine, Veterans General Hospital-Kaohsiung, Taiwan.
Cheng
D L
DL
Liu
C Y
CY
de Garis
S T
ST
Lin
H H
HH
Hsieh
T L
TL
Yen
M Y
MY
Wang
R S
RS
Chen
Y S
YS
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001170:Arthritis, Infectious / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D016470:Bacteremia / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D016576:Fleroxacin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D011446:Prospective Studies; D012074:Remission Induction; D013624:Taiwan / Q000453:epidemiology
D016576:Fleroxacin